PRIMARY infection with the human immunodeficiency virus (HIV) is generally followed by a burst of viraemia with or without clinical symptoms1–3. This in turn is followed by a prolonged period of clinical latency. During this period there is little, if any, detectable viraemia, the numbers of infected cells in the blood are very low, and it is extremely difficult to demonstrate virus expression in these cells4. We have analysed viral burden and levels of virus replication simultaneously in the blood and lymphoid organs of the same individuals at various stages of HIV disease. Here we report that in early-stage disease there is a dichotomy between the levels of viral burden and virus replication in peripheral blood versus lymphoid organs. HIV disease is active in the lymphoid tissue throughout the period of clinical latency, even at times when minimal viral activity is demonstrated in blood.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Daar, E. S., Moudgil, T., Meyer, R. D. & Ho, D. D. New Engl. J. Med. 324, 961–964 (1991).
Clark, S. J. et al. New Engl. J. Med. 324, 954–960 (1991).
Tindall, B. & Cooper, D. A. AIDS 5, 1–14 (1991).
Fauci, A. S., Schnittman, S. M., Poll, G., Koenig, S. & Pantaleo, G. Ann. Intern. Med. 114, 678–693 (1991).
Pantaleo, G. et al. Proc. natn. Acad. Sci. U.S.A. 88, 9838–9842 (1991).
Folks, T. M. et al. J. exp. Med. 164, 280–290 (1986).
Michael, N. L., Vahey, M., Burke, D. S. & Redfield, R. R. J. Virol. 66, 310–316 (1992).
Fox, C. H. et al. J. infect. Dis. 164, 1051–1057 (1991).
Racz, P. et al. Prog. Allergy 37, 81–181 (1986).
Armstrong, J. A., Dawkins, R. L. & Home, R. Immun. Today 6, 121–122 (1985).
Biberfeld, P. et al. Acta path. microbiol. immun. scand. 95, 47–65 (1987).
Armstrong, J. A. in Accessory Cells in HIV and Other Retroviral Infections (eds Racz, P., Dijkstra, C. D. & Gluckman, J. C.) 69–82 (Karger, Basel, 1991).
Spiegel, H., Herbst, H., Niedobitek, G., Foss, H. D. & Stein, H. Am. J. Path. 140, 15–22 (1992).
Emilie, D. et al. J. clin. Invest. 86, 148–159 (1990).
Tenner-Racz, K., Racz, P., Dietrich, M. & Karin, P. Lancet i, 105–106 (1985).
Haynes, B. F. in AIDS Etiology, Diagnosis, Treatment and Prevention (eds Devita, V. T. Jr et al.) 77–86 (Lippincott, Philadelphia, 1992).
Volberding, P. A. et al. New Engl. J. Med. 322, 941–949 (1990).
Clouse, K. A. et al. J. Immun. 142, 431–438 (1989).
Graziosi, C., Pantaleo, G. & Fauci, A. S. Curr. Protoc. Immun. (in the press).
Chomczynski, P. & Sacchi, N. Analyt. Biochem. 162, 156–159 (1987).
Kwok, S. et al. J. Virol. 61, 1690–1694 (1987).
Ou, C. Y. et al. Science 239, 295–297 (1988).
Schnittman, S. M., Greenhouse, J. J., Lane, H. C., Pierce, P. F. & Fauci, A. S. AIDS Res. Hum. Retrovir. 7, 361–367 (1991).
About this article
Cite this article
Pantaleo, G., Graziosi, C., Demarest, J. et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, 355–358 (1993). https://doi.org/10.1038/362355a0
Current HIV/AIDS Reports (2022)
Communications Biology (2020)
Nature Medicine (2020)
Current HIV/AIDS Reports (2019)
Engineered Nanomaterials as Potential Candidates for HIV Treatment: Between Opportunities and Challenges
Journal of Cluster Science (2019)